BUDGET IMPACT ANALYSIS OF BIOSIMILAR RITUXIMAB (CT-P10) FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN THE 28 EU MEMBER STATES
EHA Learning Center, Fanni Rencz, 182017
AN INVESTIGATION INTO THE NEEDS AND PRIORITIES OF PATIENTS WITH MULTIPLE MYELOMA DURING REMISSION - IMPLICATIONS FOR RE-DESIGNING PATIENT-CENTRED HEALTHCARE SYSTEMS.
EHA Learning Center, Dunnya DE-SILVA, 182018
COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Matthew Matthew Seftel, 182019
THE THERAPEUTIC UTILITY OF A SYSTEMATIC PROTOCOL FOR GERIATRIC ASSESMENT IN ONCOHEMATOLOGIC PATIENTS
EHA Learning Center, Claudia Milagros Terán Benzaquen, 182020
THROMBOTIC MICROANGIOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: IS THERE A PROTECTIVE ROLE FOR URSODEOXYCHOLIC ACID?
EHA Learning Center, Rocio Parody Porras, 182033
FACTORS PREDICTING GRAFT VERSUS HOST DISEASE-FREE, RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION. COMPARISON ATTENDING TO TWO DIFFERENT DEFINITIONS AND BENEFICT OF HAPLOIDENTICAL DONOR.
EHA Learning Center, María Dolores Caballero, 182034
EFFICACY AND SAFETY OF DEFIBROTIDE IN THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: FINAL SUBGROUP RESULTS
EHA Learning Center, Paul Richardson, 182035
GENERATION OF IMMORTAL MURINE HEMATOPOIETIC STEM/PROGENITOR CELL LINES FROM TRANSGENIC MICE
EHA Learning Center, Eszter Doma, 182036
INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING LOWER LIMB SURGICAL REVASCULARIZATION: IS THROMBOPROPHYLAXIS WARRANTED?
EHA Learning Center, Anmol Baranwal, 182050
GENETIC AND ENVIRONMENTAL RELATIONSHIP BETWEEN VITAMIN B12, FOLATE AND HOMOCYSTEINE AND SUSCEPTIBILITY TO THROMBOSIS IN THE GAIT 2 PROJECT. RESULTS OF A GWAS ANALYSIS.
EHA Learning Center, Angel F Remacha, 182052
CELLULAR ORIGIN OF CIRCULATING MICROPARTICLES (MP) ACCORDING TO SOMATIC MUTATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)
EHA Learning Center, Alfonso Vignoli, 182053
ARE WE TESTING APPROPRIATELY FOR THE LUPUS ANTICOAGULANT?
EHA Learning Center, Joe Sharif, 182054
FINAL ANALYSIS OF A RANDOMIZED STUDY COMPARING PROPHYLACTIC AND MRD-TRIGGERED, PRE-EMPTIVE IMATINIB AFTER HSCT FOR PH+/BCR-ABL1 POSITIVE ALL: LONG-TERM PATIENT OUTCOME AND IMPLICATIONS OF MRD ANALYSIS
EHA Learning Center, Dr. Fabian Lang, 181803
ANALYSIS OF SAFETY DATA FROM 2 MULTICENTER TRIALS OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
EHA Learning Center, Shannon Maude, 181804
UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Nicholas Short, 181805
CLINICAL IMPACT OF TET2 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS HARBORING CEBPA MUTATIONS: A STUDY OF THE AML STUDY GROUP (AMLSG)
EHA Learning Center, Frauke Theis, 181820
GFI1B - A NOVEL ONCOSUPPRESSOR WHICH RESTRICTS NUMBER OF LEUKEMIC STEM CELLS
EHA Learning Center, Aniththa Thivakaran, 181821
VARIANT ALLELE FREQUENCY KINETICS OF TYROSINE KINASE GENE MUTATIONS IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML) UNDER TREATMENT WITH AND WITHOUT DASATINIB
EHA Learning Center, Mridul Agrawal, 181822
COMPREHENSIVE MOLECULAR ANALYSIS OF ADULT MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)
EHA Learning Center, Kiyomi Morita, 181837
THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY
EHA Learning Center, Daehun kwak, 181838
VARIANT FLT3 MUTATIONS CAN BE ERADICATED BY CYTARABINE/ANTHRACYCLINE/CRENOLANIB INDUCTION IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3 (ITD/TKD) MUTANT AML
EHA Learning Center, Eunice Wang, 181839
PREVALENCE AND PROGNOSTIC VALUE OF MYD88 AND CD79B MUTATIONS IN IMMUNE-PRIVILEGED SITE AND (EXTRA)NODAL DLBCLS.
EHA Learning Center, Joost Vermaat, 181854
HIV-INFECTED PATIENTS WITH RELAPSED NON-HODGKIN LYMPHOMA (NHL) OR HODGKIN LYMPHOMA (HL): RESULTS FROM THE GERMAN HIV-RELATED LYMPHOMA COHORT STUDY
EHA Learning Center, Marcus Hentrich, 181855
RISK STRATIFICATION BASED ON NCCN-IPI AT THE TIME OF DIAGNOSIS IN COMBINATION WITH POST-TREATMENT PET-CT SCAN FOR THE TREATMENT OF NODAL PERIPHERAL T-CELL LYMPHOMA
EHA Learning Center, Deok-Hwan Yang, 181856
CLL-LIKE B-CELL CLONES FROM MBLLO INDIVIDUALS PERSIST AT INCREASED COUNTS AFTER SEVEN YEARS OF FOLLOW-UP.
EHA Learning Center, Julia Almeida, 181871
NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES
EHA Learning Center, Andrejs Braun, 181872
MICROENVIRONMENT REGULATION OF PROGRAMMED DEATH-1 (PD1) RECEPTOR AND ITS LIGANDS PDL1 AND PDL2 IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Fortunato Morabito, 181873
ROLE OF THE AURORA KINASE A/PLK 1 AXIS INHIBITION IN RESTORATION OF CELL GROWTH CONTROL OF CHRONIC MYELOID LEUKEMIA PROGENITORS
EHA Learning Center, Manuela Mancini, 181887
DURABLE TREATMENT-FREE REMISSION (TFR) FOLLOWING FRONTLINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTFREEDOM 96-WK UPDATE
EHA Learning Center, David Ross, 181888
RESPONSE DIFFERENCES IN THE BCR-ABL1 E13A2 AND E14A2 VARIANTS MAY BE A TECHNICAL QPCR ARTIFACT
EHA Learning Center, Niels Pallisgaard, 181889
CLINICAL FOLLOW-UP OF 378 PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: PROGNOSTIC IMPACT OF HEMOGLOBIN LEVELS, AUTOANTIBODY CLASS, AND RETICULOCYTOPENIA AT ONSET ON THE RELAPSE RISK AND OUTCOME
EHA Learning Center, Bruno Fattizzo, 181903
HEME BINDS ANNEXIN-A5 DURING HEMOLYSIS AND PREVENTS ITS INTERACTION WITH CELL MEMBRANE PHOSPHATIDYLSERINE DURING SICKLE CELL DISEASE
EHA Learning Center, Sihem Sadoudi, 181904
USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY
EHA Learning Center, Hemant Misra, 181905
PHASE IIIB RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) FOLLOWED BY LENALIDOMIDE VS. RITUXIMAB MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY NHL: ANALYSIS OF FOLLICULAR LYMPHOMA PATIENTS
EHA Learning Center, John Burke, 181921
A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO INNOVATOR RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA
EHA Learning Center, Michinori Ogura, 181922
DURABLE DISEASE CONTROL OF EARLY MYCOSIS FUNGOIDES PATIENTS TREATED WITH LOW-DOSE INTERFERON-ALPHA2B AND PUVA
EHA Learning Center, Serena Rupoli, 181923
TIMING OF DEFIBROTIDE INITIATION POST-DIAGNOSIS OF HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER PRIMARY CHEMOTHERAPY: EXPLORATORY ANALYSIS OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Paul Richardson, 181937
ADAMTS-13 REGULATES NEUTROPHIL RECRUITMENT IN A MOUSE MODEL OF INVASIVE PULMONARY ASPERGILLOSIS
EHA Learning Center, Astrid Hasibeder, 181938
IDENTIFICATION OF THE SPECIFIC HEMATOPOIETIC STEM CELL POPULATIONS RESPONSIBLE FOR FAILURE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Irene Ganan-Gomez, 181939
IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Ana Alfonso Pierola, 181952
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
EHA Learning Center, Aristoteles Giagounidis, 181953
RATE AND CAUSES OF 5-AZACYTIDINE DISCONTINUATION AND SUBSEQUENT THERAPEUTIC OPTIONS IN 418 MDS PATIENTS FROM THE ITALIAN MDS REGISTRY OF FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE (FISM)
EHA Learning Center, Marino Clavio, 181954
COMBINATION OF DEEP PHENOTYPING AND TARGETED NEXT GENERATION SEQUENCING AS A DIAGNOSTIC TOOL IN CHILDREN WITH SUSPECTED MDS
EHA Learning Center, Eleni Louka, 181955
PANOBINOSTAT INDUCES CD38 UPREGULATION AND AUGMENTSTHE ANTI-MYELOMA EFFICACY OF DARATUMUMAB
EHA Learning Center, Estefania Garcia-Guerrero, 181968
BCL2 EXPRESSION IS A POTENTIAL PREDICTIVE BIOMARKER OF RESPONSE TO VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jeremy Ross, 181969
THE IMPACT OF THE INTRODUCTION OF BORTEZOMIB ON DIALYSIS INDEPENDENCE IN MULTIPLE MYELOMA PATIENTS WITH RENAL FAILURE: A NATIONWIDE DUTCH POPULATION-BASED STUDY
EHA Learning Center, Berdien Oortgiesen, 181970
TREATMENT WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Paolo Milani, 181971
METHYLATION AGE IN MPN PATIENTS AS A CORRELATE FOR DISEASE STATUS, ALLELE BURDEN AND THERAPEUTIC RESPONSE
EHA Learning Center, Suzanne McPherson, 181984
ELUCIDATING THE AGE INDUCED HEMATOPOIETIC CELL-INTRINSIC AND EXTRINSIC MECHANISMS IN MYELOPROLIFERATIVE NEOPLASM INITIATION AND PROGRESSION
EHA Learning Center, Tata Nageswara Rao, 181985
PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
EHA Learning Center, Moshe Talpaz, 181986
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS:RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
EHA Learning Center, Frank Stegelmann, 181987
CHARACTERIZATION OF CD34+ HEMATOPOIETIC PRECURSORS IN INDOLENT SYSTEMIC MASTOCYTOSIS AND THEIR POTENTIAL ROLE IN EARLY DISSEMINATION OF THE DISEASE.
EHA Learning Center, Alberto Orfao, 182000
MONOALLELIC VARIANTS IN GENES RELATED TO FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: REPORT FROM THE ITALIAN REGISTRY
EHA Learning Center, Laura vinas, 182001
PRIMARY AND CONGENITAL ERYTHROCYTOSIS IN PEDIATRICS: THE EXPERIENCE OF ITALIAN CENTERS
EHA Learning Center, Giulia Geranio, 182002
NEUROLOGICAL INVOLVEMENT IN EVANS SYNDROME AND CHRONIC HEMOLYTIC AUTOIMMUNE ANEMIA OF CHILDREN: DESCRIPTION, EVOLUTION AND GENETICS
EHA Learning Center, Thomas Pincez, 182003
QUIZARTINIB AND BRIDGE TO TRANSPLANT IN FLT3-ITD AML PATIENTS AFTER FAILURE OF SALVAGE CHEMOTHERAPY: A HISTORICAL COMPARISON WITH UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) DATA
EHA Learning Center, Robert Hills, 181762
STANDARD-RISK RANDOMIZATION OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN TRIAL AIEOP-BFM ALL 2000 INDICATES EQUAL OUTCOME WITH REDUCED-INTENSITY DELAYED INTENSIFICATION IN ETV6-RUNX1-POSITIVE PATIENTS
EHA Learning Center, Kirsten Bleckmann, 181767
ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY
EHA Learning Center, Simona Soverini, 181772
STUDY OF THE EFFECT OF MIRNAS TARGETING RPS14 ON CELLULAR BIOLOGICALBEHAVIOR OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Yanbo Nie, 181777
IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE (BPX-501 CELLS) ON CHILDREN WITH LEUKEMIA GIVEN ΑLPHA-BETA T-CELL DEPLETED HAPLO-HSCT
EHA Learning Center, Pietro Merli, 181782
DISCOVERY OF ORALLY BIOAVAILABLE SMALL MOLECULES FOR INHIBITION OF COMPLEMENT C5
EHA Learning Center, Alonso Ricardo, 181787
THE SIMM STUDY: SURVEY OF INTEGRATIVE MEDICINE IN MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Krisstina gowin, 181792
A PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Philippe Moreau, 181747
SAFETY RESULTS OF TERMINATED PHASE 2 STUDY OF IDELALISIB PLUS RITUXIMAB IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH DEL(17P)
EHA Learning Center, Peter Hillmen, 181752
L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY
EHA Learning Center, Maddocks Kami J., 181757
PHASE IB/II STUDY OF NIVOLUMAB IN COMBINATION WITH AZACYTIDINE (AZA) IN PATIENTS (PTS) WITH RELAPSED ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Naval Daver, 181761
DURABLE LONG-TERM SURVIVAL OF ADULT PATIENTS WITH B-ALL AFTER CD19 CAR (19-28Z) T CELL THERAPY
EHA Learning Center, Eric Smith, 181766
COMPARISON OF GENOMIC DNA AND REVERSE TRANSCRIPTASE Q-PCR FOR THE MONITORING OF FIRST-LINE IMATINIB TREATMENT: AN ALLG CML9 SUB-STUDY
EHA Learning Center, Ilaria Stefania Pagani, 181771
IMPACT OF THE MUTATIONAL PROFILE AT THE TIME OF DIAGNOSIS IN RESPONSE OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
EHA Learning Center, Guillermo Montalban-Bravo, 181776
INDIVIDUAL OUTCOME PREDICTION FOR MDS AND SECONDARY AML AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION BASED ON GENETIC, PATIENT- AND TRANSPLANTATION-ASSOCIATED RISK FACTORS
EHA Learning Center, M. Heuser, 181781
CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA: FUNCTIONAL RESCUE OF A NOVEL MPL MUTANT IN PRIMARY HEMATOPOIETIC CELLS USING CRISPR-CAS9
EHA Learning Center, Cédric Cleyrat, 181786
FRONT-LINE VASCULAR ACCESS DEVICES IN ACUTE LEUKEMIAS - PERIPHERALLY INSERTED CENTRAL CATHETER (PICC) VERSUS TRADITIONAL CENTRAL VENOUS CATHETER (CVC): A PHASE IV RANDOMIZED TRIAL (NCT02405728)
EHA Learning Center, Claudio Cerchione, 181791
EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VERSUS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF CASTOR
EHA Learning Center, Katja C Weisel, 181746
BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
EHA Learning Center, Paula Cramer, 181751
SINGLE AGENT ORAL SELINEXOR EXHIBITS DURABLE RESPONSES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF BOTH GCB AND NON-GCB SUBTYPES: THE PHASE 2B SADAL STUDY
EHA Learning Center, Marie Maerevoet, 181756
UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAÏVE ACUTE MYELOID LEUKEMIA PATIENTS AGED ≥65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY
EHA Learning Center, Andrew Wei, 181760
BLINATUMOMAB VS SOC CHEMOTHERAPY IN FIRST SALVAGE COMPARED WITH SECOND OR GREATER SALVAGE IN A PHASE 3 STUDY
EHA Learning Center, Herve Dombret, 181765
MYC-DEPENDENT REPRESSION MECHANISM OF THE MIR-150 TRANSCRIPTIONAL REGULATION IN CHRONIC MYELOID LEUKEMIA.
EHA Learning Center, Nikola Curik, 181770
ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAÏVE AND RELAPSED/REFRACTORY PATIENTS
EHA Learning Center, Shyamala Navada, 181775
OUTCOMES OF NON T CELL-DEPLETED HAPLOIDENTICAL HSCT VERSUS HSCT FROM MATCHED SIBLING DONORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION, AN ALWP-EBMT STUDY
EHA Learning Center, Dalila Salvatore, 181780
EFFECT OF ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS WITH OR WITHOUT HIGH DISEASE ACTIVITY: RESULTS FROM THE INTERNATIONAL PNH REGISTRY
EHA Learning Center, Britta Höchsmann, 181785
EFFECTIVE KEY WORKERS REDUCE THE NEED FOR CANCER SUPPORT GROUPS: RESULTS OF A POPULATION BASED SURVEY FROM GREATER MANCHESTER CANCER PATHWAY BOARD (GMCPB).
EHA Learning Center, Jo Tomlins, 181790
OVERALL SURVIVAL OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH CARFILZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN THE RANDOMIZED PHASE 3 ENDEAVOR TRIAL
EHA Learning Center, Meletios A Dimopoulos, 181745
IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
EHA Learning Center, Nitin JAIN, 181750
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
EHA Learning Center, Matthew Matasar, 181755
CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Karen Thudium Mueller, 181764
FC GAMMA RECEPTOR 2B IS CRITICAL FOR BCR-ABL MEDIATED LEUKEMOGENESIS
EHA Learning Center, Oliver Herrmann, 181769
AN UPDATE OF A PHASE II STUDY OF NIVOLUMAB (NIVO) OR IPILIMUMAB (IPI) WITH AZACITIDINE IN PTS WITH PREVIOUSLY TREATED OR UNTREATED MYELODYSPLASTIC SYNDROMES (MDS)
EHA Learning Center, Guillermo Montalban-Bravo, 181774
IBRUTINIB FOR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER FAILURE OF FRONTLINE CORTICOSTEROIDS: RESULTS OF A MULTICENTER OPEN-LABEL PHASE 2 STUDY
EHA Learning Center, Iskra Pusic, 181779
SECONDARY LEUKEMIAS IN GENETIC SUBTYPES OF CONGENITAL NEUTROPENIA (ELANE, HAX1, WASP, G6PC3, ETC.): A LONG-TERM ANALYSIS OF THE SCNIR EUROPE
EHA Learning Center, Cornelia Zeidler, 181784
HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE PHASE III GALLIUM STUDY OF OBINUTUZUMAB-BASED AND RITUXIMAB-BASED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED INDOLENT NON-HODGKIN LYMPHOMA
EHA Learning Center, Andrew Davies, 181789
A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Joseph Mikhael, 181744
IS FCR THE TREATMENT OF CHOICE FOR IGHV MUTATED CLL WITHOUT POOR FISH CYTOGENETICS?
EHA Learning Center, carolina Cuellar, 181749
CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): PHASE IB STUDY IN RELAPSED OR REFRACTORY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, FOLLICULAR LYMPHOMA, OR MARGINAL ZONE LYMPHOMA
EHA Learning Center, R Bouabdallah, 181754
SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (≥65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Keith Pratz, 181759
GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
EHA Learning Center, Stephan A. Grupp, 181763
SERIAL SEQUENCING REVEALS CLONAL ORIGINS AND STRATEGIES FOR EARLY DETECTION OF POST-ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) RELAPSE IN ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Taehyung Kim, 181778
PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Meletios A Dimopoulos, 181743
CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC
EHA Learning Center, Panagiotis Baliakas, 181748
ENASIDENIB (AG-221) IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE-ESCALATION AND EXPANSION STUDY
EHA Learning Center, Eytan M. Stein, 181758